28.06.2016
WILEX AG DE000A11QVV0
DGAP-News: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin
DGAP-News: WILEX AG / Key word(s): Patent
WILEX AG: European Patent Office grants patent for the chemical synthetic
building block dihydroxyisoleucine for the production of Amanitin
28.06.2016 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
WILEX AG: European Patent Office grants patent for the chemical synthetic
building block dihydroxyisoleucine for the production of Amanitin
- Patent grant supports the synthetic production of Amanitin
Munich, Germany, 28 June 2016 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today announced that its subsidiary Heidelberg Pharma GmbH has been granted
a patent by the European Patent Office (EPO) for the chemical synthesis of
dihydroxyisoleucine developed by it. The patent has a term until 2033.
The amino acid dihydroxyisoleucine is an important synthetic building block
of alpha-Amanitin and of Amanitin derivatives. Without this building block
it is not possible to chemically produce Amanitin. Dihydroxyisoleucine, on
the other hand, has to be chemically produced, as there is no natural
source of it.
The patent protects the company's internal Amanitin production process,
since the production of adequate quantities of Amanitin in GMP quality for
clinical use can only be ensured by a completely chemical production of
Amanitin. After being bound to a linker and conjugated with antibodies,
alpha-Amanitin and its derivatives are used in the ATAC technology pursued
by Heidelberg Pharma.
Professor Andreas Pahl, Head of Research and Development and member of the
Executive Management Board of WILEX AG, comments: "We are very pleased that
this patent has been granted, because it protects an important building
block of our synthetic Amanitin production. It strengthens our position as
the first company worldwide to use the highly effective and innovative
compound Amanitin for ADC technology. We will continue to focus our efforts
on the full chemical production of Amanitin."
About Heidelberg Pharma's proprietary ATAC technology
Antibody drug conjugates (ADCs) combine the high affinity and specificity
of antibodies with the potential of small cytotoxic molecules for the
treatment of cancer and inflammatory diseases. ATACs are ADCs that are
bound to highly potent amatoxin molecules. Amatoxins are small bicyclic
peptides naturally occurring in the death cap mushroom. They inhibit mRNA
transcription by binding to RNA polymerase II, a mechanism that is crucial
for the survival of eukaryotic cells. Accordingly, ATACs exhibit comparable
activity against proliferating and quiescent tumour cells. This
proliferation independent activity differentiates ATACs from other ADCs,
which preferentially target proliferating tumour cells. As a potential
additional advantage ATACs could offer a substantial capability to overcome
the resistance mechanisms which might limit the efficacy of other antibody
drug conjugates.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company acting as a holding company and
Group parent. Research and development focus on the operations of its
subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances
the development of the innovative ADC platform technology for antibody-drug
conjugates based on the compound Amanitin (ATAC technology) and provides
preclinical drug research and development services. WILEX has diagnostic
and therapeutic Phase-III drug candidates, which are available for out-
licensing to external partners. WILEX is listed at the Frankfurt Stock
Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is
available at www.wilex.com
Contact IR/PR support WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Executive Director & Partner Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40 E-Mail: investors[at]wilex.com Mobil: +49 (0)160 9360 3022 Grillparzerstr. 18, 81675 E-Mail: katja.arnold[at]mc-services.eu Munich, Germany Business Development Heidelberg Pharma GmbH Dr Marcel Linssen CBO, Executive Vice President Tel.: +49 (0)6203-1009-40 E-Mail: m.linssen[at]hdpharma.comThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward- looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments. --------------------------------------------------------------------------- 28.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 18 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 474543 28.06.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6